Shares of Legend Biotech Co. (NASDAQ:LEGN – Get Rating) were down 5.7% during mid-day trading on Tuesday . The company traded as low as $47.49 and last traded at $48.12. Approximately 24,369 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 682,772 shares. The stock had previously closed at $51.01.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on LEGN shares. Guggenheim started coverage on Legend Biotech in a research note on Monday, October 31st. They issued a “neutral” rating on the stock. Evercore ISI started coverage on Legend Biotech in a research note on Tuesday, November 1st. They issued an “outperform” rating on the stock. Cowen started coverage on Legend Biotech in a research note on Tuesday, November 1st. They issued an “outperform” rating on the stock. Morgan Stanley lowered their target price on Legend Biotech from $63.00 to $60.00 and set an “overweight” rating on the stock in a research report on Thursday, October 13th. Finally, Cowen started coverage on Legend Biotech in a research report on Tuesday, November 1st. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Legend Biotech currently has an average rating of “Moderate Buy” and an average target price of $66.20.
Legend Biotech Trading Down 0.2 %
The company has a 50-day moving average of $45.28 and a two-hundred day moving average of $46.16. The company has a current ratio of 3.83, a quick ratio of 3.81 and a debt-to-equity ratio of 0.29.
Hedge Funds Weigh In On Legend Biotech
Legend Biotech Company Profile
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma.
- Get a free copy of the StockNews.com research report on Legend Biotech (LEGN)
- Three CBD Stocks to Dominate a Budding Industry
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.